Valeant Pharmaceuticals disclosed late Wednesday that it was subpoenaed by U.S. prosecutors seeking information on its pricing programs.
In early trading on Thursday, Valeant’s U.S.-listed shares were down 9% at $156.53.
Valeant under fire for increasing drug prices
Valeant Pharmaceuticals has received subpoenas from U.S. prosecutors seeking information on drug-pricing decisions. In a statement on Wednesday night, the Canada-based drug company said it recently received a subpoena from the U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office seeking information on its patient assistance programs, drug distribution and pricing decisions.
Laval, Quebec-based Valeant said the subpoenas mostly requested information about its programs to help patients pay for the company’s drugs. Valeant...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full Article
